TD Cowen lowered the firm’s price target on Privia Health to $26 from $30 and keeps an Outperform rating on the shares. The firm said Q23 results and 2024 guide were modestly below consensus though not as bad as feared.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRVA:
- Privia Health sees FY24 GAAP revenue down 3.5% to up 1% to $1.6B-$1.68B
- Privia Health reports Q4 non-GAAP EPS 15c, consensus 4c
- Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results
- Notable companies reporting before tomorrow’s open
- Privia Health assumed with a Buy at Jefferies
Questions or Comments about the article? Write to editor@tipranks.com